



Key Financial Highlights FY22

Year ended 30 June (\$m)	2022	2021	Variance	
Revenue	12,105	15,989	(3,884)	-24.3%
EBITDA	(341)	2,718	(3,058)	-112.5%
NPAT	(1,160)	2,103	(3,263)	-155.2%
Basic earnings per share	(0.5¢)	0.9¢	(1.4¢)	-155.6%

- ❖ Year-on-year Revenue decline of 24% to \$12.1 million
- ❖ Net Loss After Tax of \$1.2 million for full year 2022 which represents a year-on-year decline of 155.2%
- ❖ Year-on-year reduction in earnings per share of 155.6%
- ❖ Strong closing cash balance of \$9.2 million

Key Business Developments

- Sterile Readiness activities were completed for the Federal Government in September 2021. IDT was awarded its first ever cGMP sterile manufacturing licence from the Therapeutic Goods Administration.
- IDT's submission to the Federal Government's Approach To Market (ATM): to establish an onshore mRNA manufacturing capability, was unsuccessful, as were all other bidders in the process.
- Throughout the year in review the Company has made submissions to a range of Federal and State Government initiatives, including the ATM and the Modern Manufacturing Initiative (MMI) Collaboration and Translation stream programs.
- In November 2021, IDT utilised its sterile facility to manufacture the Monash / Doherty Institute developed receptor binding domain mRNA COVID-19 vaccine candidate, which has entered clinical trials.
- IDT continues to progress discussions with Federal and State Governments regarding Australia's pharmaceutical supply chain resilience and sovereign manufacturing of mRNA vaccines and therapeutics, as well as a range of essential medicines.
- The Company continued to execute its Medicinal Cannabis Manufacturing Plan with a range of proprietary oil-in-bottle products now on market with stability supporting a commercially appropriate shelf life.